FitLife Brands, Inc. — Form 10-Q Summary
Business Context and Reporting Period
FitLife Brands develops and sells nutritional supplements and wellness products under the NDS, iSatori, and MRC brand portfolios. Products are distributed through GNC, specialty and mass retailers, online channels, and primarily Amazon for MRC products. This unaudited filing covers the three and nine months ended September 30, 2023, compared with the same periods in 2022.
Financial Performance and Position
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Revenue | $13.902 million | $8.314 million | $39.401 million | $23.433 million |
| Gross profit | $5.696 million | $3.244 million | $16.069 million | $9.846 million |
| Gross margin | 41.0% | 39.0% | 40.8% | 42.0% |
| Operating income | $2.470 million | $1.541 million | $5.728 million | $4.963 million |
| Net income | $1.696 million | $1.220 million | $3.816 million | $3.956 million |
| Diluted EPS | $0.35 | $0.24 | $0.78 | $0.79 |
| Adjusted EBITDA | $2.545 million | $1.875 million | $7.840 million | $5.796 million |
- Q3 revenue increased 67%, gross profit increased 76%, operating income increased 60%, and net income increased 39% year over year.
- Nine-month revenue increased 68%, while net income declined 4% because of acquisition-related costs, inventory fair-value step-up amortization, and a foreign-currency hedge loss.
- Q3 operating margin was approximately 17.8% and net margin was approximately 12.2%. Nine-month operating margin was approximately 14.5% and net margin was approximately 9.7%.
- Online sales represented approximately 68% of Q3 revenue and 62% of nine-month revenue, compared with 26% in both comparable 2022 periods. GNC represented 30% of Q3 revenue and 34% of nine-month revenue, down from 69% in each 2022 comparable period.
- Cash provided by operating activities was $2.772 million for the nine months, down from $5.003 million. Investing cash use was $18.984 million, primarily for the MRC acquisition and a MusclePharm deposit. Financing cash flow was $11.250 million from term-loan borrowings, net of repayments.
- At September 30, 2023, cash and cash equivalents were $7.343 million, restricted cash was $969 thousand, and working capital was approximately $12.139 million. Total assets were $43.972 million and stockholders’ equity was $25.249 million.
- Debt consisted of an $11.250 million term-loan balance; the $3.5 million revolving line of credit had no outstanding balance. The term loan bears interest at Term SOFR plus 2.75% and matures February 28, 2028. The company reported compliance with all debt covenants at quarter-end.
Material Changes Versus the Prior Comparable Period
- The February 28, 2023 acquisition of Mimi’s Rock Corp. added the MRC product portfolio and was the principal driver of reported revenue growth. MRC contributed $7.202 million of Q3 revenue and $1.162 million of Q3 net income.
- Legacy FitLife revenue declined 19% in Q3 and 6% for the first nine months, as lower wholesale revenue more than offset online growth. Management cited a 14% decline in wholesale retail movement during Q3.
- Nine-month gross margin decreased 1.2 percentage points because of inflationary product costs and $323 thousand of amortization related to the MRC inventory fair-value step-up. Excluding that amortization, reported nine-month gross margin would have been 41.6%.
- SG&A increased 90% for the first nine months, and merger and acquisition costs increased to $1.519 million from $214 thousand.
- Cash declined from $13.277 million at December 31, 2022 to $7.343 million at September 30, 2023, largely because acquisition spending exceeded operating and financing inflows.
Outlook, Risks, Contingencies, and Unusual Items
- Management expects cash from operations, existing cash, and available revolver capacity to be sufficient for the next 12 months, but states that failure to generate positive operating cash flow or access additional working capital could materially harm the business.
- Management expects online revenue to continue increasing relative to prior periods and views e-commerce expansion and the MusclePharm acquisition as potential growth drivers. No formal quantitative revenue or earnings guidance was provided.
- On October 10, 2023, after quarter-end, the company acquired substantially all MusclePharm assets for approximately $18.5 million in cash. The purchase was funded with $10.0 million of new term debt and the remainder from cash. The acquired assets primarily consist of intellectual property, and valuation remains in process.
- The October 2023 financing increased leverage through the new $10.0 million Term B Loan, which matures October 10, 2028. The filing does not provide post-transaction debt or liquidity balances.
- Key risks include inflation and the ability to pass higher costs to customers, reliance on GNC and significant vendors, foreign-exchange and interest-rate exposure, acquisition integration and valuation uncertainty, goodwill impairment risk, and dependence on operating cash flow and credit availability.
- The MRC acquisition accounting remains provisional, including approximately $7.746 million of intangible assets and $13.321 million of goodwill at September 30, 2023. No goodwill impairment indicators were identified.
- The company reported no material litigation and no material changes to the risk factors disclosed in its 2022 Form 10-K. Management concluded that disclosure controls were effective as of September 30, 2023 after implementing a remediation plan for previously identified material weaknesses.
Important Facts for Investors to Verify
- Reconcile reported growth with the contribution from MRC and assess the decline in Legacy FitLife revenue and wholesale demand.
- Review the final purchase-price allocation for MRC and the valuation of its provisional goodwill and intangible assets.
- Assess post-quarter-end leverage, interest expense, covenant compliance, and liquidity following the MusclePharm acquisition and $10.0 million Term B Loan.
- Evaluate whether the shift toward online sales improves sustainable margins and offsets inflation, fulfillment costs, and customer concentration.
- Review the company’s ability to convert reported earnings into operating cash flow, particularly after acquisition-related payments and working-capital changes.
- Confirm the effect of the subsequent exercise of all outstanding warrants and any resulting share-count or dilution changes.